Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement

Journal of Veterinary Internal Medicine

Volumn 19, Issue 1, 2005, Pages 74-80

  Fan, Timothy M ^a   De Lorimier, Louis Philippe ^a   Charney, Sarah C ^a   Hintermeister, John G ^a,b  

^a Veterinary Teaching Hospital   (United States)

^b Veterinary Specialty Clinic   (United States)

Author keywords

Aminobisphosphonate; Canine; Dual energy x ray absorptiometry; Hypercalcemia; Pain; Urine N telopeptide

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CREATININE; NITROGEN; PAMIDRONIC ACID; UREA;

ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE METASTASIS; CHEMICAL ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG SCREENING; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; MALE; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; OSTEOSARCOMA; REDUCTION; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE NEOPLASMS; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; DENSITOMETRY, X-RAY; DIPHOSPHONATES; DOG DISEASES; DOGS; FEMALE; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; OSTEOSARCOMA; PEPTIDES;

ANIMALIA; CANIS FAMILIARIS;

EID: 13544263450     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2005)19<74:EOIPAI>2.0.CO;2     Document Type: Article

References (44)

1. Schibler D, Russell RG, Fleisch H. Inhibition by pyrophosphate and polyphosphate on aortic calcification induced by vitamin D3 in rats. Clin Sci 1968;35:363-372.
2. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966;212:901-903.
3. Fleisch HA, Russell RG, Bisaz S, et al. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970;1:12-18.
4. Mautalen CA, Gonzalez D, Ghiringhelli G. Efficacy of the bisphosphonate APD in the control of Paget's bone disease. Bone 1985;6:429-432.
5. Hosking DJ. Prediction and assessment of the response of Paget's disease to bisphosphonate treatment. Bone 1999;24(5 Suppl):69-71.
6. Sparidans RW, Twiss IM, Talbot S. Bisphosphonates in bone diseases. Pharm World Sci 1998;20:206-213.
7. Harris ST. Bisphosphonates for the treatment of postmenopausal osteoporosis: Clinical studies of etidronate and alendronate. Osteoporos Int 2001;12(3 Suppl):11-16.
8. Woo T, Adachi JD. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis. Best Pract Res Clin Rheumatol 2001;15:469-481.
9. Fleisch H. Bisphosphonates: Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42:919-944.
10. Carano A, Teitelbaum SL, Konsek JD, et al. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990;85:456-461.
11. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
12. Selander KS, Monkkonen J, Karhukorpi EK, et al. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996;50:1127-1138.
13. Licata AA. Bisphosphonate therapy. Am J Med Sci 1997;313:17-22.
14. Banerjee D, Asif A, Striker L, et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity [review]. Am J Kidney Dis. 2003;41:E18.
15. Markowitz GS, Fine PL, D'agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis. 2002;39:1118-1122.
16. Lockridge L, Papac RJ, Perazella MA. Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis. Am J Kidney Dis 2002;40:E2.
17. Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004;65:634-641.
18. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164-1172.
19. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000;88(12 Suppl):2952-2960.
20. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000;88(12 Suppl):2919-2926.
21. Rosen HN, Moses AC, Garber J, et al. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-103.
22. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-2026.
23. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850-856.
24. Bachrach LK. Dual energy X-ray absorptiometry (DEXA) measurements of bone density and body composition: Promise and pitfalls. J Pediatr Endocrinol Metab 2000;13(Suppl 2):983-988.
25. Kirk JK, Nichols M, Spangler JG. Use of a peripheral dexa measurement for osteoporosis screening. Fam Med 2002;34:201-205.
26. Berruti A, Dogliotti L, Osella G, et al. Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. Oncol Rep 2000;7:777-781.
27. Shapiro CL, Keating J, Angell JE, et al. Monitoring therapeutic response in skeletal metastases using dual-energy x-ray absorptiometry: A prospective feasibility study in breast cancer patients. Cancer Invest 1999;17:566-574.
28. Tarvainen R, Arnala I, Nevalainen T, et al. Clodronate increases bone mineral density in young growing oophorectomized beagles. Ann Chir Gynaecol 1995;84:304-308.
29. Lauten SD, Cox NR, Brawner WR Jr, et al. Use of dual energy x-ray absorptiometry for noninvasive body composition measurements in clinically normal dogs. Am J Vet Res 2001;62:1295-1301.
30. Ehrhart N, Eurell JA, Tommasini M, et al. Effect of cisplatin on bone transport osteogenesis in dogs. Am J Vet Res 2002;63:703-711.
31. Ladlow JF, Hoffmann WE, Breur GJ, et al. Biological variability in serum and urinary indices of bone formation and resorption in dogs. Calcif Tissue Int 2002;70:186-193.
32. Vinholes JJF, Purohit OP, Abbey ME, et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997;8:1243-1250.
33. Cascinu S, Graziano F, Alessandroni P, et al. Different doses of pamidronate in patients with osteolytic bone metastases. Support Care Cancer 1998;6:139-143.
34. Koeberle D, Bacchus L, Thurlimann B, Senn HJ. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: A prospective randomized double-blind trial. Support Care Cancer 1999;7:21-27.
35. Body JJ, Dumon JC. Treatment of tumor-induced hypercalcemia with the bisphosphonates pamidronate: Dose-response relationship and influence of the tumor type. Ann Oncol 1994;5:359-363.
36. Tomlin JL, Sturgeon C, Pead MJ, Muir P. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet Rec 2000;147:129-132.
37. Pesillo SA, Khan SA, Rozanski EA, et al. Calcipotriene toxicosis in a dog successfully treated with pamidronate disodium. J Vet Emerg Crit Care 2002;12:177-181.
38. Kadar E, Rush JE, Wetmore L, et al. Electrolyte disturbances and cardiac arrhythmias in a dog following pamidronate, calcitonin, and furosemide administration for hypercalcemia of malignancy. J Am Anim Hosp Assoc. 2004;40:75-81.
39. Rumbeiha WK, Fitzgerald SD, Kruger JM, et al. Use of pamidronate disodium to reduce cholecalciferol-induced toxicosis in dogs. Am J Vet Res 2000;61:9-13.
40. 3-induced toxicosis in dogs. Am J Vet Res 1999;60:1092-1097.
41. McEntee MC, Page RL, Novotney CA, et al. Palliative radiotherapy for canine appendicular osteosarcoma. Vet Radiol Ultrasound 1993;34:367-370.
42. Bateman KE, Catton PA, Pennock PW, et al. 0-7-12 Radiation therapy for the palliation of advance cancer in dogs. J Vet Intern Med 1994;8:394-399.
43. Ramirez O III, Dodge RK, Page RL, et al. Palliative radiotherapy of appendicular osteosarcoma of 95 dogs. Vet Radiol Ultrasound 1999;40:517-522.
44. Green EM, Adam WM, Forrest LJ. Four fraction palliative radiotherapy for osteosarcoma in 24 dogs. J Am Anim Hosp Assoc 2002;38:445-451.